^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Topoisomerase I inhibitor

    Related drugs:
    1d
    Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01) (clinicaltrials.gov)
    P1, N=200, Recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Feb 2027 --> Oct 2026 | Trial primary completion date: Feb 2027 --> Oct 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • leucovorin calcium • precemtabart tocentecan (M9140)
    1d
    Exosomal hnRNPA2B1 suppresses irinotecan-induced ferroptosis in pancreatic cancer. (PubMed, Hepatobiliary Pancreat Dis Int)
    These findings indicated that exosomal hnRNPA2B1 could inhibit irinotecan-induced ferroptosis of PC, which strongly regulated the progression and drug resistance of PC.
    Journal
    |
    GPX4 (Glutathione Peroxidase 4) • SLC7A11 (Solute Carrier Family 7 Member 11) • HNRNPA2B1 (Heterogeneous Nuclear Ribonucleoprotein A2/B1)
    |
    irinotecan
    1d
    A bispecific nanobody-drug conjugate targeting TROP2 and c-Met for low-concentration, single-dose treatment of pancreatic cancer. (PubMed, Cell Rep Med)
    In preclinical studies, B6ADC exhibits potent cytotoxicity in vitro across various TROP2/c-Met-expressing cancer cell lines and superior tumor inhibition in vivo compared with single-target ADC combination, including the clinically approved TROP2 ADC sacituzumab govitecan and c-Met ADC Teliso-V, as well as their combination. Notably, B6ADC eradicates giant tumors with a single dose at a low concentration of 2.2 mg/kg. We present a nanobody-based BsADC that simultaneously targets TROP2 and c-Met, with broad-spectrum antitumor activity, and improves selectivity for tumors with dual-positive or weakly positive antigen expression, offering a promising strategy for treating pancreatic cancer and other TROP2/c-Met-expressing malignancies.
    Journal
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    MET expression
    |
    Trodelvy (sacituzumab govitecan-hziy) • Emrelis (telisotuzumab vedotin-tllv)
    1d
    Genotyping of DPYD and UGT1A1 in Brazilian oncological patients: applying pharmacogenomics in an admixed population. (PubMed, Rev Assoc Med Bras (1992))
    The presence of DPYD and UGT1A1 variants is considerable among Brazilian gastrointestinal cancer patients, reinforcing the promising use of pre-therapeutic genetic tests for irinotecan and fluoropyrimidines to avoid severe toxicities related to treatment. Genetic panels for these variants must be continuously updated and adapted for population-specific characteristics.
    Journal
    |
    UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    irinotecan
    1d
    Anti-CEACAM5 ADC Precemtabart Tocentecan (M9140) in Chinese Participants With Solid Tumors (clinicaltrials.gov)
    P1, N=12, Active, not recruiting, Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • BRAF wild-type
    |
    precemtabart tocentecan (M9140)
    1d
    SGN35C-001: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers (clinicaltrials.gov)
    P1, N=57, Active, not recruiting, Seagen, a wholly owned subsidiary of Pfizer | Trial completion date: Apr 2029 --> Apr 2026 | Trial primary completion date: Apr 2028 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    TNFRSF8 (TNF Receptor Superfamily Member 8)
    |
    TNFRSF8 expression
    |
    PF-08046044
    1d
    TROP-LUNG: A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy (clinicaltrials.gov)
    P2, N=25, Recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion
    |
    Ivesa (firmonertinib) • Jiataile (sacituzumab tirumotecan)
    2d
    GEMINI-PeriOp GC: A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma (clinicaltrials.gov)
    P2, N=100, Recruiting, AstraZeneca
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CLDN18 (Claudin 18)
    |
    HER-2 positive • HER-2 negative • CLDN18.2 positive • CLDN18.2 positive + HER-2 negative
    |
    docetaxel • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • sonesitatug vedotin (AZD0901) • rilvegostomig (AZD2936)
    2d
    A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Anti-tumor Efficacy of HDM2024 in Participants With Advanced Solid Tumors (ChiCTR2600121689)
    P1, N=63, Shanghai East Hospital; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    2d
    A Multicenter, Open-Label, Phase 1a/b First-in-Human Study to Investigate the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BG-C477 in Patients with Selected Advanced Solid Tumors (ChiCTR2600121742)
    P1, N=230, Recruiting, Sun Yat-sen University Cancer Center (Sun Yat-sen University Cancer Hospital, Sun Yat-sen University Cancer Institute); Sun Yat-sen University Cancer
    New P1 trial • First-in-human
    |
    MSI-H/dMMR
    |
    Avastin (bevacizumab) • capecitabine • Avzivi (bevacizumab-tnjn)
    2d
    HS-20093-309: A Multicenter, Randomized, Open-Label, Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined with Adebrelimab versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer without Actionable Genomic Alterations (ChiCTR2600121048)
    P3, N=450, Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
    New P3 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CD276 (CD276 Molecule)
    |
    PD-L1 expression • EGFR mutation • ALK fusion • ALK mutation • ROS1 fusion
    |
    docetaxel • AiRuiLi (adebrelimab) • risvutatug rezetecan (GSK5764227)
    2d
    Sacituzumab Tirumotecan in Combination with Anlotinib in Previously Treated Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC): A Prospective, Single-Arm, Phase II Study (ChiCTR2600120856)
    P2, N=33, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)